Original document(20 pages)  中文版
    The present invention provides the application of shikonin in preparing medicine for inducing apoptosis. Shikonin has the molecular formula of C16H16O5 and the chemical name of (+)-5, 8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1, 4-naphthoquinone, possesses optical activity, and constitutes one pair of antimers together with isoshikonin. The present invention has clinical application foreground owing to that shikonin can kill several kinds of drug resisting tumor cells in the effect higher than other available clinical medicines and possesses relatively low toxicity.
Application Number
申请号
200610053627 Application Date
申请日
2006.09.27
Title 名称 Application of shikonin in preparing medicine for inducing apoptosis
Publication Number
公开号
1931152 Publication Date
公开日
2007.03.21
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K31/122;A61K9/00;A61K36/30;A61P35/00;A61K125/00
Applicant(s) Name
申请人
Zhejiang Univ.
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人 zhangfa gao zhaohang li
More information 更  多  信  息


 Related patents information
Testing mass spectrum model of blood serum protein in carcinoma of large intestine and its creating method
Multidrug resistance reverse agent for tumor
Usage of cytochalasin D in the preparing process of anticancer medicine
Use of alkannin in preparing medicine for treating tumor disease
Usage of honokiol in the preparing process of anti tumor angiopoiesis medicine
Application Hehoupu phenol in preparing antitumour multi medicinal tolerant medicine
Application of Schisandrin-B in preparing medicine for treating tumor
Novel bacillus named BARB and its uses
Application of biphenyl cyclo-octadiene lignans for reducing toxic and side effect of antitumor agent
Application of honokiol in preparing medicine for treating acute leukemia
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.